Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 31 entries
Sorted by: Best Match Show Resources per page
Transition of Mount Etna lavas from a mantle-plume to an island-arc magmatic source.

Nature

Schiano P, Clocchiatti R, Ottolini L, Busà T.
PMID: 11528476
Nature. 2001 Aug 30;412(6850):900-4. doi: 10.1038/35091056.

Mount Etna lies near the boundary between two regions that exhibit significantly different types of volcanism. To the north, volcanism in the Aeolian island arc is thought to be related to subduction of the Ionian lithosphere. On Sicily itself,...

Cite
Schiano P, Clocchiatti R, Ottolini L, et al. Transition of Mount Etna lavas from a mantle-plume to an island-arc magmatic source. Nature. 2001;412(6850):900-4doi: 10.1038/35091056.
Schiano, P., Clocchiatti, R., Ottolini, L., & Busà, T. (2001). Transition of Mount Etna lavas from a mantle-plume to an island-arc magmatic source. Nature, 412(6850), 900-4. https://doi.org/10.1038/35091056
Schiano, P, et al. "Transition of Mount Etna lavas from a mantle-plume to an island-arc magmatic source." Nature vol. 412,6850 (2001): 900-4. doi: https://doi.org/10.1038/35091056
Schiano P, Clocchiatti R, Ottolini L, Busà T. Transition of Mount Etna lavas from a mantle-plume to an island-arc magmatic source. Nature. 2001 Aug 30;412(6850):900-4. doi: 10.1038/35091056. PMID: 11528476.
Copy Download .nbib Format: NLM
Accurate quantification of H, Li, Be, B, F, Ba, REE, Y, Th, and U in complex matrixes: a combined approach based on SIMS and single-crystal structure refinement.

Analytical chemistry

Ottolini L, Oberti R.
PMID: 10959956
Anal Chem. 2000 Aug 15;72(16):3731-8. doi: 10.1021/ac0002240.

A procedure was developed for accurate quantification of REE, actinides, and light elements in complex matrixes of interest in earth and material sciences (hellandite and britholite, the REE analogue of apatite). These minerals show a peculiar chemical composition due...

Cite
Ottolini L, Oberti R. Accurate quantification of H, Li, Be, B, F, Ba, REE, Y, Th, and U in complex matrixes: a combined approach based on SIMS and single-crystal structure refinement. Anal Chem. 2000;72(16):3731-8doi: 10.1021/ac0002240.
Ottolini, L., & Oberti, R. (2000). Accurate quantification of H, Li, Be, B, F, Ba, REE, Y, Th, and U in complex matrixes: a combined approach based on SIMS and single-crystal structure refinement. Analytical chemistry, 72(16), 3731-8. https://doi.org/10.1021/ac0002240
Ottolini, and Oberti. "Accurate quantification of H, Li, Be, B, F, Ba, REE, Y, Th, and U in complex matrixes: a combined approach based on SIMS and single-crystal structure refinement." Analytical chemistry vol. 72,16 (2000): 3731-8. doi: https://doi.org/10.1021/ac0002240
Ottolini L, Oberti R. Accurate quantification of H, Li, Be, B, F, Ba, REE, Y, Th, and U in complex matrixes: a combined approach based on SIMS and single-crystal structure refinement. Anal Chem. 2000 Aug 15;72(16):3731-8. doi: 10.1021/ac0002240. PMID: 10959956.
Copy Download .nbib Format: NLM
Correction: Immunological Characterization of Whole Tumour Lysate-Loaded Dendritic Cells for Cancer Immunotherapy.

PloS one

Rainone V, Martelli C, Ottobrini L, Biasin M, Texido G, Degrassi A, Borelli M, Lucignani G, Trabattoni D, Clerici M.
PMID: 26934596
PLoS One. 2016 Mar 02;11(3):e0151008. doi: 10.1371/journal.pone.0151008. eCollection 2016.

No abstract available.

Cite
Rainone V, Martelli C, Ottobrini L, et al. Correction: Immunological Characterization of Whole Tumour Lysate-Loaded Dendritic Cells for Cancer Immunotherapy. PLoS One. 2016;11(3):e0151008doi: 10.1371/journal.pone.0151008.
Rainone, V., Martelli, C., Ottobrini, L., Biasin, M., Texido, G., Degrassi, A., Borelli, M., Lucignani, G., Trabattoni, D., & Clerici, M. (2016). Correction: Immunological Characterization of Whole Tumour Lysate-Loaded Dendritic Cells for Cancer Immunotherapy. PloS one, 11(3), e0151008. https://doi.org/10.1371/journal.pone.0151008
Rainone, Veronica, et al. "Correction: Immunological Characterization of Whole Tumour Lysate-Loaded Dendritic Cells for Cancer Immunotherapy." PloS one vol. 11,3 (2016): e0151008. doi: https://doi.org/10.1371/journal.pone.0151008
Rainone V, Martelli C, Ottobrini L, Biasin M, Texido G, Degrassi A, Borelli M, Lucignani G, Trabattoni D, Clerici M. Correction: Immunological Characterization of Whole Tumour Lysate-Loaded Dendritic Cells for Cancer Immunotherapy. PLoS One. 2016 Mar 02;11(3):e0151008. doi: 10.1371/journal.pone.0151008. eCollection 2016. PMID: 26934596; PMCID: PMC4775054.
Copy Download .nbib Format: NLM
Role of Metformin and AKT Axis Modulation in the Reversion of Hypoxia Induced TMZ-Resistance in Glioma Cells.

Frontiers in oncology

Lo Dico A, Valtorta S, Ottobrini L, Moresco RM.
PMID: 31214505
Front Oncol. 2019 May 31;9:463. doi: 10.3389/fonc.2019.00463. eCollection 2019.

Hypoxia is a key driver of tumor adaptation promoting tumor progression and resistance to therapy. Hypoxia related pathways might represent attractive targets for the treatment of Glioblastoma Multiforme (GBM), that up to date is characterized by a poor prognosis....

Cite
Lo Dico A, Valtorta S, Ottobrini L, et al. Role of Metformin and AKT Axis Modulation in the Reversion of Hypoxia Induced TMZ-Resistance in Glioma Cells. Front Oncol. 2019;9:463doi: 10.3389/fonc.2019.00463.
Lo Dico, A., Valtorta, S., Ottobrini, L., & Moresco, R. M. (2019). Role of Metformin and AKT Axis Modulation in the Reversion of Hypoxia Induced TMZ-Resistance in Glioma Cells. Frontiers in oncology, 9463. https://doi.org/10.3389/fonc.2019.00463
Lo Dico, Alessia, et al. "Role of Metformin and AKT Axis Modulation in the Reversion of Hypoxia Induced TMZ-Resistance in Glioma Cells." Frontiers in oncology vol. 9 (2019): 463. doi: https://doi.org/10.3389/fonc.2019.00463
Lo Dico A, Valtorta S, Ottobrini L, Moresco RM. Role of Metformin and AKT Axis Modulation in the Reversion of Hypoxia Induced TMZ-Resistance in Glioma Cells. Front Oncol. 2019 May 31;9:463. doi: 10.3389/fonc.2019.00463. eCollection 2019. PMID: 31214505; PMCID: PMC6554426.
Copy Download .nbib Format: NLM
Survival of Patients Treated with Antibiotics and Immunotherapy for Cancer: A Systematic Review and Meta-Analysis.

Journal of clinical medicine

Petrelli F, Iaculli A, Signorelli D, Ghidini A, Dottorini L, Perego G, Ghidini M, Zaniboni A, Gori S, Inno A.
PMID: 32414103
J Clin Med. 2020 May 13;9(5). doi: 10.3390/jcm9051458.

Antibiotics (ABs) are common medications used for treating infections. In cancer patients treated with immune checkpoint inhibitors (ICIs), concomitant exposure to ABs may impair the efficacy of ICIs and lead to a poorer outcome compared to AB non-users. We...

Cite
Petrelli F, Iaculli A, Signorelli D, et al. Survival of Patients Treated with Antibiotics and Immunotherapy for Cancer: A Systematic Review and Meta-Analysis. J Clin Med. 2020;9(5)doi: 10.3390/jcm9051458.
Petrelli, F., Iaculli, A., Signorelli, D., Ghidini, A., Dottorini, L., Perego, G., Ghidini, M., Zaniboni, A., Gori, S., & Inno, A. (2020). Survival of Patients Treated with Antibiotics and Immunotherapy for Cancer: A Systematic Review and Meta-Analysis. Journal of clinical medicine, 9(5), . https://doi.org/10.3390/jcm9051458
Petrelli, Fausto, et al. "Survival of Patients Treated with Antibiotics and Immunotherapy for Cancer: A Systematic Review and Meta-Analysis." Journal of clinical medicine vol. 9,5 (2020). doi: https://doi.org/10.3390/jcm9051458
Petrelli F, Iaculli A, Signorelli D, Ghidini A, Dottorini L, Perego G, Ghidini M, Zaniboni A, Gori S, Inno A. Survival of Patients Treated with Antibiotics and Immunotherapy for Cancer: A Systematic Review and Meta-Analysis. J Clin Med. 2020 May 13;9(5). doi: 10.3390/jcm9051458. PMID: 32414103; PMCID: PMC7290584.
Copy Download .nbib Format: NLM
One-step Reprogramming of Human Fibroblasts into Oligodendrocyte-like Cells by SOX10, OLIG2, and NKX6.2.

Stem cell reports

Chanoumidou K, Hernández-Rodríguez B, Windener F, Thomas C, Stehling M, Mozafari S, Albrecht S, Ottoboni L, Antel J, Kim KP, Velychko S, Cui QL, Xu YKT, Martino G, Winkler J, Schöler HR, Baron-Van Evercooren A, Boespflug-Tanguy O, Vaquerizas JM, Ehrlich M, Kuhlmann T.
PMID: 33770499
Stem Cell Reports. 2021 Apr 13;16(4):771-783. doi: 10.1016/j.stemcr.2021.03.001. Epub 2021 Mar 25.

Limited access to human oligodendrocytes impairs better understanding of oligodendrocyte pathology in myelin diseases. Here, we describe a method to robustly convert human fibroblasts directly into oligodendrocyte-like cells (dc-hiOLs), which allows evaluation of remyelination-promoting compounds and disease modeling. Ectopic...

Cite
Chanoumidou K, Hernández-Rodríguez B, Windener F, et al. One-step Reprogramming of Human Fibroblasts into Oligodendrocyte-like Cells by SOX10, OLIG2, and NKX6.2. Stem Cell Reports. 2021;16(4):771-783doi: 10.1016/j.stemcr.2021.03.001.
Chanoumidou, K., Hernández-Rodríguez, B., Windener, F., Thomas, C., Stehling, M., Mozafari, S., Albrecht, S., Ottoboni, L., Antel, J., Kim, K. P., Velychko, S., Cui, Q. L., Xu, Y. K. T., Martino, G., Winkler, J., Schöler, H. R., Baron-Van Evercooren, A., Boespflug-Tanguy, O., Vaquerizas, J. M., Ehrlich, M., & Kuhlmann, T. (2021). One-step Reprogramming of Human Fibroblasts into Oligodendrocyte-like Cells by SOX10, OLIG2, and NKX6.2. Stem cell reports, 16(4), 771-783. https://doi.org/10.1016/j.stemcr.2021.03.001
Chanoumidou, Konstantina, et al. "One-step Reprogramming of Human Fibroblasts into Oligodendrocyte-like Cells by SOX10, OLIG2, and NKX6.2." Stem cell reports vol. 16,4 (2021): 771-783. doi: https://doi.org/10.1016/j.stemcr.2021.03.001
Chanoumidou K, Hernández-Rodríguez B, Windener F, Thomas C, Stehling M, Mozafari S, Albrecht S, Ottoboni L, Antel J, Kim KP, Velychko S, Cui QL, Xu YKT, Martino G, Winkler J, Schöler HR, Baron-Van Evercooren A, Boespflug-Tanguy O, Vaquerizas JM, Ehrlich M, Kuhlmann T. One-step Reprogramming of Human Fibroblasts into Oligodendrocyte-like Cells by SOX10, OLIG2, and NKX6.2. Stem Cell Reports. 2021 Apr 13;16(4):771-783. doi: 10.1016/j.stemcr.2021.03.001. Epub 2021 Mar 25. PMID: 33770499; PMCID: PMC8072064.
Copy Download .nbib Format: NLM
Imaging Metformin Efficacy as Add-On Therapy in Cells and Mouse Models of Human EGFR Glioblastoma.

Frontiers in oncology

Valtorta S, Lo Dico A, Raccagni I, Martelli C, Pieri V, Rainone P, Todde S, Zinnhardt B, De Bernardi E, Coliva A, Politi LS, Viel T, Jacobs AH, Galli R, Ottobrini L, Vaira V, Moresco RM.
PMID: 34012924
Front Oncol. 2021 May 03;11:664149. doi: 10.3389/fonc.2021.664149. eCollection 2021.

Glioblastoma (GBM) is a highly aggressive tumor of the brain. Despite the efforts, response to current therapies is poor and 2-years survival rate ranging from 6-12%. Here, we evaluated the preclinical efficacy of Metformin (MET) as add-on therapy to...

Cite
Valtorta S, Lo Dico A, Raccagni I, et al. Imaging Metformin Efficacy as Add-On Therapy in Cells and Mouse Models of Human EGFR Glioblastoma. Front Oncol. 2021;11:664149doi: 10.3389/fonc.2021.664149.
Valtorta, S., Lo Dico, A., Raccagni, I., Martelli, C., Pieri, V., Rainone, P., Todde, S., Zinnhardt, B., De Bernardi, E., Coliva, A., Politi, L. S., Viel, T., Jacobs, A. H., Galli, R., Ottobrini, L., Vaira, V., & Moresco, R. M. (2021). Imaging Metformin Efficacy as Add-On Therapy in Cells and Mouse Models of Human EGFR Glioblastoma. Frontiers in oncology, 11664149. https://doi.org/10.3389/fonc.2021.664149
Valtorta, Silvia, et al. "Imaging Metformin Efficacy as Add-On Therapy in Cells and Mouse Models of Human EGFR Glioblastoma." Frontiers in oncology vol. 11 (2021): 664149. doi: https://doi.org/10.3389/fonc.2021.664149
Valtorta S, Lo Dico A, Raccagni I, Martelli C, Pieri V, Rainone P, Todde S, Zinnhardt B, De Bernardi E, Coliva A, Politi LS, Viel T, Jacobs AH, Galli R, Ottobrini L, Vaira V, Moresco RM. Imaging Metformin Efficacy as Add-On Therapy in Cells and Mouse Models of Human EGFR Glioblastoma. Front Oncol. 2021 May 03;11:664149. doi: 10.3389/fonc.2021.664149. eCollection 2021. PMID: 34012924; PMCID: PMC8126706.
Copy Download .nbib Format: NLM
Transcriptomic Analysis of Peripheral Monocytes upon Fingolimod Treatment in Relapsing Remitting Multiple Sclerosis Patients.

Molecular neurobiology

Sferruzza G, Clarelli F, Mascia E, Ferrè L, Ottoboni L, Sorosina M, Santoro S, Moiola L, Martinelli V, Comi G, Martinelli Boneschi F, Filippi M, Provero P, Esposito F.
PMID: 34181235
Mol Neurobiol. 2021 Oct;58(10):4816-4827. doi: 10.1007/s12035-021-02465-z. Epub 2021 Jun 28.

Fingolimod (FTY), a second-line oral drug approved for relapsing remitting Multiple Sclerosis (RRMS) acts in preventing lymphocyte migration outside lymph nodes; moreover, several lines of evidence suggest that it also inhibits myeloid cell activation. In this study, we investigated...

Cite
Sferruzza G, Clarelli F, Mascia E, et al. Transcriptomic Analysis of Peripheral Monocytes upon Fingolimod Treatment in Relapsing Remitting Multiple Sclerosis Patients. Mol Neurobiol. 2021;58(10):4816-4827doi: 10.1007/s12035-021-02465-z.
Sferruzza, G., Clarelli, F., Mascia, E., Ferrè, L., Ottoboni, L., Sorosina, M., Santoro, S., Moiola, L., Martinelli, V., Comi, G., Martinelli Boneschi, F., Filippi, M., Provero, P., & Esposito, F. (2021). Transcriptomic Analysis of Peripheral Monocytes upon Fingolimod Treatment in Relapsing Remitting Multiple Sclerosis Patients. Molecular neurobiology, 58(10), 4816-4827. https://doi.org/10.1007/s12035-021-02465-z
Sferruzza, G, et al. "Transcriptomic Analysis of Peripheral Monocytes upon Fingolimod Treatment in Relapsing Remitting Multiple Sclerosis Patients." Molecular neurobiology vol. 58,10 (2021): 4816-4827. doi: https://doi.org/10.1007/s12035-021-02465-z
Sferruzza G, Clarelli F, Mascia E, Ferrè L, Ottoboni L, Sorosina M, Santoro S, Moiola L, Martinelli V, Comi G, Martinelli Boneschi F, Filippi M, Provero P, Esposito F. Transcriptomic Analysis of Peripheral Monocytes upon Fingolimod Treatment in Relapsing Remitting Multiple Sclerosis Patients. Mol Neurobiol. 2021 Oct;58(10):4816-4827. doi: 10.1007/s12035-021-02465-z. Epub 2021 Jun 28. PMID: 34181235.
Copy Download .nbib Format: NLM
Mantle thermal pulses below the Mid-Atlantic Ridge and temporal variations in the formation of oceanic lithosphere.

Nature

Bonatti E, Ligi M, Brunelli D, Cipriani A, Fabretti P, Ferrante V, Gasperini L, Ottolini L.
PMID: 12774114
Nature. 2003 May 29;423(6939):499-505. doi: 10.1038/nature01594.

A 20-Myr record of creation of oceanic lithosphere is exposed along a segment of the central Mid-Atlantic Ridge on an uplifted sliver of lithosphere. The degree of melting of the mantle that is upwelling below the ridge, estimated from...

Cite
Bonatti E, Ligi M, Brunelli D, et al. Mantle thermal pulses below the Mid-Atlantic Ridge and temporal variations in the formation of oceanic lithosphere. Nature. 2003;423(6939):499-505doi: 10.1038/nature01594.
Bonatti, E., Ligi, M., Brunelli, D., Cipriani, A., Fabretti, P., Ferrante, V., Gasperini, L., & Ottolini, L. (2003). Mantle thermal pulses below the Mid-Atlantic Ridge and temporal variations in the formation of oceanic lithosphere. Nature, 423(6939), 499-505. https://doi.org/10.1038/nature01594
Bonatti, Enrico, et al. "Mantle thermal pulses below the Mid-Atlantic Ridge and temporal variations in the formation of oceanic lithosphere." Nature vol. 423,6939 (2003): 499-505. doi: https://doi.org/10.1038/nature01594
Bonatti E, Ligi M, Brunelli D, Cipriani A, Fabretti P, Ferrante V, Gasperini L, Ottolini L. Mantle thermal pulses below the Mid-Atlantic Ridge and temporal variations in the formation of oceanic lithosphere. Nature. 2003 May 29;423(6939):499-505. doi: 10.1038/nature01594. PMID: 12774114.
Copy Download .nbib Format: NLM
A Review of Clinical Practice Guidelines and Treatment Recommendations for Cancer Care in the COVID-19 Pandemic.

Cancers

Zaniboni A, Ghidini M, Grossi F, Indini A, Trevisan F, Iaculli A, Dottorini L, Moleri G, Russo A, Vavassori I, Brevi A, Rausa E, Boni L, Dondossola D, Valeri N, Ghidini A, Tomasello G, Petrelli F.
PMID: 32872421
Cancers (Basel). 2020 Aug 29;12(9). doi: 10.3390/cancers12092452.

The COVID-19 pandemic has inevitably caused those involved in cancer care to change clinical practice in order to minimize the risk of infection while maintaining cancer treatment as a priority. General advice during the pandemic suggests that most patients...

Cite
Zaniboni A, Ghidini M, Grossi F, et al. A Review of Clinical Practice Guidelines and Treatment Recommendations for Cancer Care in the COVID-19 Pandemic. Cancers (Basel). 2020;12(9)doi: 10.3390/cancers12092452.
Zaniboni, A., Ghidini, M., Grossi, F., Indini, A., Trevisan, F., Iaculli, A., Dottorini, L., Moleri, G., Russo, A., Vavassori, I., Brevi, A., Rausa, E., Boni, L., Dondossola, D., Valeri, N., Ghidini, A., Tomasello, G., & Petrelli, F. (2020). A Review of Clinical Practice Guidelines and Treatment Recommendations for Cancer Care in the COVID-19 Pandemic. Cancers, 12(9), . https://doi.org/10.3390/cancers12092452
Zaniboni, Alberto, et al. "A Review of Clinical Practice Guidelines and Treatment Recommendations for Cancer Care in the COVID-19 Pandemic." Cancers vol. 12,9 (2020). doi: https://doi.org/10.3390/cancers12092452
Zaniboni A, Ghidini M, Grossi F, Indini A, Trevisan F, Iaculli A, Dottorini L, Moleri G, Russo A, Vavassori I, Brevi A, Rausa E, Boni L, Dondossola D, Valeri N, Ghidini A, Tomasello G, Petrelli F. A Review of Clinical Practice Guidelines and Treatment Recommendations for Cancer Care in the COVID-19 Pandemic. Cancers (Basel). 2020 Aug 29;12(9). doi: 10.3390/cancers12092452. PMID: 32872421; PMCID: PMC7565383.
Copy Download .nbib Format: NLM
Therapeutic Plasticity of Neural Stem Cells.

Frontiers in neurology

Ottoboni L, von Wunster B, Martino G.
PMID: 32265815
Front Neurol. 2020 Mar 20;11:148. doi: 10.3389/fneur.2020.00148. eCollection 2020.

Neural stem cells (NSCs) have garnered significant scientific and commercial interest in the last 15 years. Given their plasticity, defined as the ability to develop into different phenotypes inside and outside of the nervous system, with a capacity of...

Cite
Ottoboni L, von Wunster B, Martino G. Therapeutic Plasticity of Neural Stem Cells. Front Neurol. 2020;11:148doi: 10.3389/fneur.2020.00148.
Ottoboni, L., von Wunster, B., & Martino, G. (2020). Therapeutic Plasticity of Neural Stem Cells. Frontiers in neurology, 11148. https://doi.org/10.3389/fneur.2020.00148
Ottoboni, Linda, et al. "Therapeutic Plasticity of Neural Stem Cells." Frontiers in neurology vol. 11 (2020): 148. doi: https://doi.org/10.3389/fneur.2020.00148
Ottoboni L, von Wunster B, Martino G. Therapeutic Plasticity of Neural Stem Cells. Front Neurol. 2020 Mar 20;11:148. doi: 10.3389/fneur.2020.00148. eCollection 2020. PMID: 32265815; PMCID: PMC7100551.
Copy Download .nbib Format: NLM
Neural Stem Cell Plasticity: Advantages in Therapy for the Injured Central Nervous System.

Frontiers in cell and developmental biology

Ottoboni L, Merlini A, Martino G.
PMID: 28553634
Front Cell Dev Biol. 2017 May 12;5:52. doi: 10.3389/fcell.2017.00052. eCollection 2017.

The physiological and pathological properties of the neural germinal stem cell niche have been well-studied in the past 30 years, mainly in animals and within given limits in humans, and knowledge is available for the cyto-architectonic structure, the cellular...

Cite
Ottoboni L, Merlini A, Martino G. Neural Stem Cell Plasticity: Advantages in Therapy for the Injured Central Nervous System. Front Cell Dev Biol. 2017;5:52doi: 10.3389/fcell.2017.00052.
Ottoboni, L., Merlini, A., & Martino, G. (2017). Neural Stem Cell Plasticity: Advantages in Therapy for the Injured Central Nervous System. Frontiers in cell and developmental biology, 552. https://doi.org/10.3389/fcell.2017.00052
Ottoboni, Linda, et al. "Neural Stem Cell Plasticity: Advantages in Therapy for the Injured Central Nervous System." Frontiers in cell and developmental biology vol. 5 (2017): 52. doi: https://doi.org/10.3389/fcell.2017.00052
Ottoboni L, Merlini A, Martino G. Neural Stem Cell Plasticity: Advantages in Therapy for the Injured Central Nervous System. Front Cell Dev Biol. 2017 May 12;5:52. doi: 10.3389/fcell.2017.00052. eCollection 2017. PMID: 28553634; PMCID: PMC5427132.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 31 entries